October 19, 2010 — CardioGen-82 (Rubidium Rb 82 Generator) when used with positron emission tomography (PET) myocardial perfusion imaging (MPI) has been shown to produce “reasonably low radiation exposure” of 3.7mSv for a complete rest/stress study. 1

Confirmed in the recently published study “Human Biodistribution and Radiation Dosimetry of 82Rb,” led by Frank Bengel, M.D., of Johns Hopkins University and featured in the October issue of Journal of Nuclear Medicine, this finding is added testament to the enhanced diagnostic ability and safety of this PET myocardial perfusion tracer.

“As the number of cardiovascular imaging procedures continues to increase, the concerns over radiation exposure have become an important issue. Our study provides scientific evidence for this discussion,” Bengel said. “It resolves a discrepancy between previously available estimates of radiation dose from rubidium-82. It confirms that rubidium-82 PET is at the lower end of radiation dose among cardiac imaging procedures involving ionizing radiation.”

Bengel evaluated 10 healthy volunteers who underwent dynamic PET/computed tomography (CT) — six contiguous table positions, each with separate 82Rb infusion. Source organ volumes of interest were delineated on the CT images and transferred to the PET images to obtain time-integrated activity coefficients. From the study, Dr. Bengel concluded that the current 82Rb dosimetry suggests reasonably low radiation exposure. On the basis of this study, a clinical 82Rb injection of 2 . 1,480 MBq (80 mCi) would result in a mean effective dose of 3.7 mSv using the weighting factors of the ICRP 103 – only slightly above the average annual natural background exposure in the United States (3.1 mSv). 1

Reference:
1. Bengel et al. Human Biodistribution and Radiation Dosimetry of 82Rb. Journal of Nuclear Medicine. 2010.

For more information: www.braccoimaging.com


Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
Subscribe Now